These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 25454689

  • 1. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
    Macpherson IR, Bray C, Hopkins C, Hannon RA, Lewsley LA, Ritchie DM, Canney P.
    Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
    [Abstract] [Full Text] [Related]

  • 2. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 3. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ, Kurth AH, Sittig HB, Meden H, Maasberg M, Sandermann A, Bergner R.
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [Abstract] [Full Text] [Related]

  • 4. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer.
    Wang R, Zhang S, Jiang Z, Tian J, Wang T, Song S.
    Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):88-93. PubMed ID: 27716993
    [Abstract] [Full Text] [Related]

  • 5. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [Abstract] [Full Text] [Related]

  • 6. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 20; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 8. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R.
    Int J Clin Oncol; 2011 Jun 20; 16(3):264-9. PubMed ID: 21240683
    [Abstract] [Full Text] [Related]

  • 9. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N, Silverman SL, Simonelli C, Santiago N, Kohles JD, Dasic G, Sunyecz JA.
    Osteoporos Int; 2009 Sep 20; 20(9):1595-601. PubMed ID: 19145396
    [Abstract] [Full Text] [Related]

  • 10. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M, Dranitsaris G, Ooi W, Cole DE.
    Breast Cancer Res Treat; 2008 Mar 20; 108(1):79-85. PubMed ID: 17473981
    [Abstract] [Full Text] [Related]

  • 11. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn KJ, Kanis J.
    Ann Oncol; 1999 Mar 20; 10(3):311-6. PubMed ID: 10355575
    [Abstract] [Full Text] [Related]

  • 12. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
    Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, Tripathy D, Bergstrom B.
    Br J Cancer; 2004 Mar 22; 90(6):1133-7. PubMed ID: 15026791
    [Abstract] [Full Text] [Related]

  • 13. Ibandronate: its role in metastatic breast cancer.
    Cameron D, Fallon M, Diel I.
    Oncologist; 2006 Mar 22; 11 Suppl 1():27-33. PubMed ID: 16971737
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug 22; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 15. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B, MF 4434 Study Group.
    Ann Oncol; 2004 May 22; 15(5):743-50. PubMed ID: 15111341
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
    Altundag K, Dizdar O, Ozsaran Z, Ozkok S, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M, Karahoca M.
    Onkologie; 2012 May 22; 35(5):254-8. PubMed ID: 22868504
    [Abstract] [Full Text] [Related]

  • 17. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 22; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 18. Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
    Yaman E, Benekli M, Coskun U, Ozturk B, Kaya AO, Yildiz R, Buyukberber S.
    Ann Oncol; 2008 Feb 22; 19(2):397-8; author reply 398. PubMed ID: 18260185
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 22; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 20. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
    von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M.
    Ann Oncol; 2008 Jul 22; 19(7):1266-1270. PubMed ID: 18334511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.